Clinical trial
Somatropin Treatment in Patients With SHOX Deficiency and Turner Syndrome
NCT00190658 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00190658 |
|---|---|
| Title | Somatropin Treatment in Patients With SHOX Deficiency and Turner Syndrome |
| Official title | Safety and Efficacy of Humatrope in Pediatric Patients With Genetic Short Stature (SHOX Gene Defect) |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Failure to Thrive |
| Intervention type | Drug |
| Interventions | Somatropin (rDNA origin) for injection |
| Enrollment | 75 |
| Start date | Feb 1, 2000 |
| Primary completion | Jul 1, 2004 |
| Completion | Sep 1, 2010 |
| First posted | Sep 19, 2005 |
| Last update posted | Dec 20, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: